The Life Sciences Report
WATCHLIST 2013
With three quarters in the books, are the biotech companies that made The Life Sciences Report Watchlist 2013 meeting expectations? The Watchlist was built on the opinions of experts with experience in the space. The company stats as of Oct. 21, along with those of leading biotech indices, are tabulated below.
| Analyst | Company |
Market Cap M = Million B = Billion |
Year to Date (as of 4/22/13) |
|
|---|---|---|---|---|
|
Raghuram “Ram” Selvaraju Managing Director and Head of Healthcare Equity Research Aegis Capital |
Ariad Pharmaceuticals Inc. (ARIA:NASDAQ) Amarin Corporation plc (AMRN:NASDAQ) Medivation Inc. (MDVN:NASDAQ) Trius Therapeutics Inc. (TSRX:NASDAQ) |
$563M $397M $3.98B Acquired for $658M |
-85% -72% -3% +185% at acquisition |
|
|
John McCamant Editor Medical Technology Stock Letter |
Sangamo BioSciences Inc. (SGMO:NASDAQ) Pharmacyclics Inc. (PCYC:NASDAQ) |
$575M $9.5B |
+74% +107% |
|
|
Mike King Senior Analyst & Managing Director JMP Securities |
Navidea Biopharmaceuticals Inc. (NAVB:NYSE) Celsion Corp. (CLSN:NASDAQ) Onyx Pharmaceuticals Inc. (ONXX:NASDAQ) Sarepta Therapeutics Inc. (SRPT:NASDAQ) |
$259M $73M Acquired for $9.7B $1.4B |
-25% -85% +61% at acquisition +58% |
|
|
Lisa Bayko
Senior Analyst JMP Securities |
Hyperion Therapeutics Inc. (HPTX:NASDAQ) | $463M | +103% | |
|
George Zavoico Senior Biotechnology Analyst MLV & Co. |
Prana Biotechnology Ltd. (PRAN:NASDAQ) Peregrine Pharmaceuticals (PPHM:NASDAQ) |
$152M $217M |
+69% +4% |
|
|
Mara Goldstein Senior Biotechnology Analyst Cantor Fitzgerald |
Celldex Therapeutics Inc. (CLDX:NASDAQ) Galena Biopharma Inc. (GALE:NASDAQ) Celgene Corp. (CELG:NASDAQ) NewLink Genetics Corp. (NLNK:NASDAQ) |
$2.9B $186M $66B $442M |
+235% +39% +96% +45% |
Indices |
| NYSEArca Biotechnology (BTK) | +32% year to date | |||
| NASDAQ Biotechnology (NBI) | +44% year to date | |||
| George S. Mack, The Life Sciences Report | ||||
